Current Treatment Insights
Understand Today’s Standard of Care, Prepare for Tomorrow
Our treatment landscape assessments map how patients move through existing therapies and how treatment patterns shape market dynamics. Our treatment landscape analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. We also provide the use of treatments by a line of therapy, and their KOL-perceived advantages and disadvantages. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities, and their treatment, including treatment switches, polypharmacy, compliance, and persistence, is conducted.
What We Provide:
- Current Standard of Care (SoC) across 7MM & emerging markets
- Treatment Algorithm Mapping across major markets
- Physician Practice Pattern Insights
- Therapy-Class & Brand-Level Benchmarking
- Efficacy, Safety, Dosing & Differentiation Analysis
- Real-World Utilization Trends (switching, persistence, adherence)
- Pipeline vs. Standard-of-Care Gap Analysis
How It Helps You:
- Identify commercial white spaces
- Understand why physicians choose certain therapies (differentiation points)
- Benchmark products vs. competitors
- TPP design
- Refine global and local launch strategies
What Strategic Answers Clients Will Receive:
- What are physicians currently prescribing, and why?
- How do treatment algorithms differ across geographies and clinical settings?
- Which therapies dominate the market, and what factors drive their adoption?
- What are the real-world utilization patterns (switching, adherence, persistence)?
- Where are the gaps, dissatisfaction areas, or pain points with current treatment options?
- How can new therapies position themselves relative to today’s standard of care?
Reports:
Market Outlook and Forecast
Thelansis’s “Lamb-Shaffer Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lamb-Shaffer Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Severe Eosinophilic Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Eosinophilic Asthma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Vanishing White Matter Disease (VWMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vanishing White Matter Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Arginine Vasopressin Deficiency (AVP-D) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Arginine Vasopressin Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Locally Advanced or Metastatic HER2-Negative Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Locally Advanced or Metastatic HER2-Negative Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Access and Reimbursement Insights
Thelansis’s “Dyslipidemia Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.

